CClinicalTrials.gg
CompletedNCT06123130VALID-ECGUpdated Jul 5, 2024

AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia Detection

An interventional study of Vectorcardiography (VECG) in Arrhythmias, Cardiac, Atrial Fibrillation and Atrial Flutter, sponsored by HeartBeam, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by HeartBeam, Inc. · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is a prospective single-arm multicenter clinical trial. Adult patients will be consented and enrolled in an outpatient cardiology office or Arrhythmia Clinics.

Read the detailed description

The purpose of this study is to conduct clinical validation of the AIMIGo 12-lead Synthesis Software against a standard FDA-cleared 12-lead ECG system, based on quantitative and qualitative assessment of paired recordings from the same patient, in sinus rhythm or during episodes of symptomatic non-life-threatening arrhythmia. The study will provide the necessary data for an FDA 510(k) regulatory submission and develop experience for market access and integration into clinical workflows.

02

Conditions studied

  • Arrhythmias, Cardiac
  • Atrial Fibrillation
  • Atrial Flutter
  • Bradycardia
  • Tachycardia

Keywords

  • Telemedicine
  • Cardiac Arrhythmia
  • ECG
  • Synthesis Software
  • Diagnostic
  • Vectorcardiography
  • Remote Monitoring
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female subjects over 18 years of age.
  2. Referred to outpatient arrhythmia clinic with a history of one or more of the following conditions:

    1. Previous diagnosis of arrhythmia presenting to the clinic for routine follow-up evaluation.
    2. Patients with symptoms indicative of cardiac arrhythmias.
  3. Able and willing to sign informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Open chest wounds or recent (\<30 days) surgery to the chest or abdomen.
  2. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol.
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    Single Arm

    The study is a prospective single-arm multicenter clinical trial. Adult patients will be consented and enrolled in an outpatient cardiology office or Arrhythmia Clinic.

    Device: Vectorcardiography (VECG)

Interventions

  • DeviceVectorcardiography (VECG)

    Patients enrolled will undergo diagnostic ECG recording: three sets of simultaneous 30s recordings with the investigational device AIMIGo and a standard 12L ECG.

    Also known as: HeartBeam AIMIGo VECG System

05

What researchers measure

Primary outcomes

  1. Clinical equivalence of ECG intervals compared between AIMIGo Synthesized 12L and reference standard 12L

    Quantitative analysis on ECG intervals of the median beat of a 30s simultaneously recorded ECG from study and reference device.

    Time frame: 30 seconds recording

  2. Clinical equivalence of ECG amplitudes compared between AIMIGo Synthesized 12L and reference standard 12L

    Quantitative analysis on ECG amplitudes of the median beat of a 30s simultaneously recorded ECG from study and reference device.

    Time frame: 30 seconds recording

Secondary outcomes

  1. Clinical diagnostic accuracy of AIMIGo Synthesized 12L compared with the reference standard 12L ECG for the classification of arrhythmia.

    Summary statistics demonstrating agreement on arrhythmia diagnoses between the two devices will be performed

    Time frame: 30 seconds recording

06

Study locations

5 sites
  • Piedmont Heart Institute
    Atlanta, Georgia 30309, United States
  • Atlanta Heart Specialists
    Tucker, Georgia 30084, United States
  • The Mount Sinai Hospital
    New York, New York 10029, United States
  • Long Island Jewish Medical Center
    Queens, New York 11040, United States
  • Allegheny Health Network
    Pittsburgh, Pennsylvania 15212, United States
07

References and documents

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT06123130
Lead sponsor
HeartBeam, Inc.
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Mar 13, 2024
Primary completion
Jun 20, 2024
Completion
Jun 20, 2024
Last update
Jul 5, 2024

Study contacts

Peter J. Fitzgerald, MD, PhD
study director · HeartBeam, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion